Acceding to the recommendation of an independent data monitoring committee (DMC), Eli Lilly and Co. said it was terminating the phase III ACCELERATE study of evacetrapib (formerly LY2484595) in high-risk atherosclerotic cardiovascular disease (CVD) for lack of efficacy, bringing the program to an abrupt end. Read More
Progenics Pharmaceuticals Inc., of Tarrytown, N.Y., said data from its phase II study with Azedra (Ultratrace iobenguane I 131) for the treatment of ultra-orphan indications pheochromocytoma and paraganglioma were highlighted during an oral presentation at the European Association of Nuclear Medicine Congress in Hamburg, Germany. Read More
Medgenics Inc., of Philadelphia, said it completed an underwritten public offering of 7.07 million shares of its common stock, of $6.50 per share, including 923,250 shares sold as a result of the exercise of the underwriters option to purchase additional shares. Read More
Voyager Therapeutics Inc., a gene therapy company advancing adeno-associated virus (AAV) treatments for five central nervous system (CNS) disorders, has filed to raise up to $86.3 million in a yet-to-price IPO. The Cambridge, Mass.-based company, formed by Third Rock Ventures, plans to list its shares on Nasdaq under the symbol VYGR. Read More
HONG KONG – In a deal that is likely to open the door of the Chinese and global market to an early stage South Korean drug developer, 3Sbio Inc (HK:2530) signed an exclusive agreement to develop, manufacture and market an antibody drug conjugate (ADC) that targets the HER2 pathway for cancer. Read More
Nemus Bioscience Inc., a company cultivating close ties with the U.S. government's sole licensed marijuana grower, the University of Mississippi (UM), landed a $5 million series B financing in August. Read More
Smokers have plenty of options to quit, but many restart because of chronic "smoker's cough" caused by mucus buildup in the lungs that forms after they stop smoking. Read More
The EMA launched an initiative to make better use of patient registries as a source of post-authorization data for regulatory decision-making and to facilitate the development of new registries. Read More
Basilea Pharmaceutica Ltd., of Basel, Switzerland, said Health Canada approved Zevtera (ceftobiprole medocaril) to treat those 18 and older with hospital-acquired pneumonia, excluding ventilator-associated pneumonia, and with community-acquired pneumonia. Read More
